RyboDyn Raises $10 Million in Seed Funding
RyboDyn, a San Diego-based biotech company, has successfully raised $10 million in a seed funding round dated March 24, 2026. The company specializes in developing innovative immunotherapies by leveraging AI and high-resolution RNA sequencing through its proprietary RyboCypher™ platform.
Company Overview
RyboDyn focuses on unlocking the dark proteome, which encompasses proteins that are not yet fully understood, to create first-in-class immunotherapies. This cutting-edge approach aims to address complex medical challenges by utilizing advanced computational techniques and RNA sequencing.
Leadership Team
The company is co-founded by a team of experts in computational biology and business strategy. Imad Ajjawi, PhD, MBA serves as the CEO, bringing a strong background in both scientific research and business operations. Ashley Woodfin, Co-Founder and Chief Computational Officer, plays a key role in the technological advancements of the company. Kerry Wilson, Vice President and Co-Founder, rounds out the leadership team with her extensive experience in the biotech industry.
Use of Funds
Details on the specific allocation of the $10 million raised have not been disclosed. However, it is anticipated that the funds will be instrumental in furthering the development of RyboCypher™ and expanding research capabilities. This infusion of capital is expected to accelerate RyboDyn's efforts to bring novel immunotherapies to market.
Investors
The funding round did not specify any lead investors or additional participants. The company has not disclosed any further details regarding the investors involved.
Location and Impact
Based in San Diego, California, RyboDyn is well-positioned within a vibrant biotech hub. The region's rich ecosystem offers ample opportunities for collaboration and innovation, which could prove beneficial as the company scales its operations.
With this substantial seed funding, RyboDyn is poised to make significant strides in the field of immunotherapy, potentially offering new solutions for patients with unmet medical needs. As the company continues to develop its technology, it may pave the way for breakthroughs in treating complex diseases.